


## PHARMACEUTICAL 2021



## Viatris Inc Rank 91 of 409







## PHARMACEUTICAL 2021



## Viatris Inc Rank 91 of 409



The relative strengths and weaknesses of Viatris Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viatris Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 153% points. The greatest weakness of Viatris Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is 49%, being 404% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	12,867,500
Cost of Goods Sold	8,149,300
Intangible Assets	42,030,200
Liabilities, Current	10,562,900
Liabilities, Non-Current	24,912,300
Other Assets	3,195,400
Other Compr. Net Income	939,200
Other Expenses	554,300
Other Liabilities	3,123,700
Other Net Income	-12,600
Property and Equipment	3,459,900
Research and Development	555,100
Revenues	11,946,000
Selling, General and Administrative Expense	3,344,600

Output Variable	Value in 1000 USD
Assets	61,553,000
Liabilities	38,598,900
Expenses	12,603,300
Stockholders Equity	22,954,100
Net Income	-669,900
Comprehensive Net Income	-200,300
Economic Capital Ratio	49%